Globus Medical Projects $3.22B Revenue for Fiscal 2026 Amid Strong Q4 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy GMED?
Source: Fool
- Optimistic Financial Outlook: Globus Medical projects Q4 2025 revenue of $823.2 million, representing a 25.2% year-over-year growth, significantly exceeding analysts' expectations of $778.3 million, highlighting the company's strong growth potential in the orthopedic market.
- Improved Profitability: The company anticipates diluted adjusted earnings per share (EPS) for fiscal 2026 to be between $4.30 and $4.40, surpassing the analyst consensus of $4.12, indicating management's confidence in future profitability.
- Positive Market Reaction: Despite a nearly 3% drop during regular trading hours, Globus Medical's stock surged 9.9% in after-hours trading following the earnings report, reflecting investor optimism about the company's prospects.
- Successful Acquisition Integration: CFO Kyle Kline noted that the strong Q4 performance not only demonstrates above-market growth but also indicates ongoing success in integrating the NuVasive and Nevro acquisitions, enhancing the company's competitive position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMED
Wall Street analysts forecast GMED stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 87.220
Low
87.00
Averages
101.00
High
114.00
Current: 87.220
Low
87.00
Averages
101.00
High
114.00
About GMED
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Globus Medical Upgraded to Buy by Needham with $112 Target
- Rating Upgrade: Needham upgraded Globus Medical Inc. (NYSE:GMED) from Hold to Buy with a price target of $112, reflecting positive expectations for the company's financial performance following its preliminary fourth-quarter revenue announcement.
- Improved Earnings Outlook: Analysts at Needham highlighted expanding EBITDA margins, particularly an estimated 20% EBITDA margin for Nevro, which is expected to drive earnings expectations for fiscal 2026, potentially lifting earnings per share guidance by a high-single to low-double digit percentage.
- Organic Growth Potential: The analysts believe that improving organic revenue growth could lead to upside relative to Globus's existing revenue guidance, further enhancing investor confidence in the company's prospects.
- International Market Expansion: On January 26, TD Cowen initiated coverage on Globus with a Buy rating and a $110 price target, noting growth opportunities in its Nevro segment, international market expansion, and enabling technologies, despite facing significant negative sentiment, the long-term earnings outlook remains favorable.
See More
Geneva Capital Sells Shares of Ollie's Bargain Outlet
- Share Sale Details: Geneva Capital Management sold 95,151 shares of Ollie's Bargain Outlet in Q4 2026, with an estimated transaction value of $11.47 million, demonstrating the firm's adaptability amid market fluctuations.
- Ownership Percentage Change: Following the sale, Geneva's stake in Ollie's decreased from 2.34% to 2.13%, indicating a cautious approach towards the stock while still retaining a degree of investment confidence.
- Market Performance Analysis: As of February 11, 2026, Ollie's shares were priced at $113.75, reflecting a 10% increase over the year, yet underperforming the S&P 500 by 4.39 percentage points, suggesting mixed market expectations for future growth.
- Expansion Plans: Ollie's opened 86 new stores and acquired Big Lots in fiscal 2025, showcasing its commitment to expansion in an uncertain economic environment, potentially laying the groundwork for future revenue growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Changes: The rating changes include upgrades, downgrades, and new initiations, showcasing analysts' responsiveness to market dynamics, which may prompt investors to reassess their portfolios.
- Investor Focus: For those considering buying LUV stock, analysts' perspectives will serve as a crucial reference, impacting their timing and strategy, potentially affecting the stock's short-term performance.
- Market Information Source: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, urging investors to monitor these changes to optimize their investment strategies.
See More
Bone Grafts Market Report: Forecast to 2036
- Market Size Forecast: The report indicates significant growth in the bone grafts and substitutes market projected by 2036, with detailed intervention volumes and market value data across 39 countries aiding strategic decision-making for businesses.
- Product Segmentation Analysis: It provides an in-depth analysis of various bone graft substitutes, including allograft bone chips and bone morphogenetic proteins, offering insights into market share and average selling prices to help companies optimize their product portfolios.
- Competitive Dynamics Insights: Through SWOT analysis and exploration of competitive dynamics, the report reveals the market positions of key players such as Medtronic and Stryker, assisting investors in identifying potential investment opportunities.
- Market Access Strategies: Additionally, the report offers detailed information on market access, including reimbursement policies and regulatory landscapes, enabling companies to formulate effective market entry strategies in a complex environment.
See More
Globus Medical CFO Kyle Kline Sells 3,594 Shares
- Executive Sell-off: On January 8, 2026, Globus Medical's CFO Kyle Kline sold 3,594 shares, which may raise concerns about the company's future performance, as executive sell-offs are often perceived as negative signals regarding company outlook.
- Market Reaction: While the specific sale price was not disclosed, executive stock transactions can significantly impact investor confidence, potentially leading to short-term stock price volatility, prompting investors to closely monitor subsequent market developments.
- Governance Concerns: Such executive sell-offs may trigger scrutiny of the company's governance structure, particularly regarding transparency and executive stock incentives, possibly prompting the company to enhance internal governance measures to maintain investor trust.
- Investor Strategy Adjustment: Investors may reassess their investment strategies in Globus Medical based on this news, especially in the current market environment, necessitating caution regarding the potential risks associated with executive sell-offs.
See More
US Stocks Close Mixed on Thursday as Tech Sector Faces Pressure
- Market Volatility: The S&P 500 Index closed up 0.01% while the Dow Jones Industrial Average rose 0.55%, and the Nasdaq 100 fell 0.57%, indicating mixed market performance amid weakness in tech stocks.
- Economic Data Impact: Initial jobless claims in the US rose by 8,000 to 208,000, lower than the expected 212,000, suggesting a strong labor market that could influence Fed policy in a hawkish direction.
- Military Spending Expectations: President Trump announced plans to increase the US military budget by 50% to $1.5 trillion by 2027, leading to a rally in defense stocks, with AeroVironment rising over 8%.
- Energy Market Rebound: Energy producers surged as WTI crude oil prices rose by more than 3%, with APA Corp leading gains in the S&P 500, up over 8%.
See More
Globus Medical Upgraded to Buy by Needham with $112 Target
- Rating Upgrade: Needham upgraded Globus Medical Inc. (NYSE:GMED) from Hold to Buy with a price target of $112, reflecting positive expectations for the company's financial performance following its preliminary fourth-quarter revenue announcement.
- Improved Earnings Outlook: Analysts at Needham highlighted expanding EBITDA margins, particularly an estimated 20% EBITDA margin for Nevro, which is expected to drive earnings expectations for fiscal 2026, potentially lifting earnings per share guidance by a high-single to low-double digit percentage.
- Organic Growth Potential: The analysts believe that improving organic revenue growth could lead to upside relative to Globus's existing revenue guidance, further enhancing investor confidence in the company's prospects.
- International Market Expansion: On January 26, TD Cowen initiated coverage on Globus with a Buy rating and a $110 price target, noting growth opportunities in its Nevro segment, international market expansion, and enabling technologies, despite facing significant negative sentiment, the long-term earnings outlook remains favorable.
See More
Geneva Capital Sells Shares of Ollie's Bargain Outlet
- Share Sale Details: Geneva Capital Management sold 95,151 shares of Ollie's Bargain Outlet in Q4 2026, with an estimated transaction value of $11.47 million, demonstrating the firm's adaptability amid market fluctuations.
- Ownership Percentage Change: Following the sale, Geneva's stake in Ollie's decreased from 2.34% to 2.13%, indicating a cautious approach towards the stock while still retaining a degree of investment confidence.
- Market Performance Analysis: As of February 11, 2026, Ollie's shares were priced at $113.75, reflecting a 10% increase over the year, yet underperforming the S&P 500 by 4.39 percentage points, suggesting mixed market expectations for future growth.
- Expansion Plans: Ollie's opened 86 new stores and acquired Big Lots in fiscal 2025, showcasing its commitment to expansion in an uncertain economic environment, potentially laying the groundwork for future revenue growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Changes: The rating changes include upgrades, downgrades, and new initiations, showcasing analysts' responsiveness to market dynamics, which may prompt investors to reassess their portfolios.
- Investor Focus: For those considering buying LUV stock, analysts' perspectives will serve as a crucial reference, impacting their timing and strategy, potentially affecting the stock's short-term performance.
- Market Information Source: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, urging investors to monitor these changes to optimize their investment strategies.
See More
Bone Grafts Market Report: Forecast to 2036
- Market Size Forecast: The report indicates significant growth in the bone grafts and substitutes market projected by 2036, with detailed intervention volumes and market value data across 39 countries aiding strategic decision-making for businesses.
- Product Segmentation Analysis: It provides an in-depth analysis of various bone graft substitutes, including allograft bone chips and bone morphogenetic proteins, offering insights into market share and average selling prices to help companies optimize their product portfolios.
- Competitive Dynamics Insights: Through SWOT analysis and exploration of competitive dynamics, the report reveals the market positions of key players such as Medtronic and Stryker, assisting investors in identifying potential investment opportunities.
- Market Access Strategies: Additionally, the report offers detailed information on market access, including reimbursement policies and regulatory landscapes, enabling companies to formulate effective market entry strategies in a complex environment.
See More
Globus Medical CFO Kyle Kline Sells 3,594 Shares
- Executive Sell-off: On January 8, 2026, Globus Medical's CFO Kyle Kline sold 3,594 shares, which may raise concerns about the company's future performance, as executive sell-offs are often perceived as negative signals regarding company outlook.
- Market Reaction: While the specific sale price was not disclosed, executive stock transactions can significantly impact investor confidence, potentially leading to short-term stock price volatility, prompting investors to closely monitor subsequent market developments.
- Governance Concerns: Such executive sell-offs may trigger scrutiny of the company's governance structure, particularly regarding transparency and executive stock incentives, possibly prompting the company to enhance internal governance measures to maintain investor trust.
- Investor Strategy Adjustment: Investors may reassess their investment strategies in Globus Medical based on this news, especially in the current market environment, necessitating caution regarding the potential risks associated with executive sell-offs.
See More
US Stocks Close Mixed on Thursday as Tech Sector Faces Pressure
- Market Volatility: The S&P 500 Index closed up 0.01% while the Dow Jones Industrial Average rose 0.55%, and the Nasdaq 100 fell 0.57%, indicating mixed market performance amid weakness in tech stocks.
- Economic Data Impact: Initial jobless claims in the US rose by 8,000 to 208,000, lower than the expected 212,000, suggesting a strong labor market that could influence Fed policy in a hawkish direction.
- Military Spending Expectations: President Trump announced plans to increase the US military budget by 50% to $1.5 trillion by 2027, leading to a rally in defense stocks, with AeroVironment rising over 8%.
- Energy Market Rebound: Energy producers surged as WTI crude oil prices rose by more than 3%, with APA Corp leading gains in the S&P 500, up over 8%.
See More
